Baseline characteristics of the entire cohort of 844 patients
| Presentation and initial treatment | |
| Age, years | 62.5 (54.3, 70.2) |
| Man | 77.9 |
| Admission diagnosis | |
| STEMI | 51.7 |
| NSTEMI | 37.7 |
| UAP | 10.6 |
| Culprit artery | |
| RCA | 33.1 |
| LM | 2.5 |
| LAD | 31.9 |
| LCX | 16.5 |
| Coronary angiography performed | 94.4 |
| Percutaneous coronary intervention | 86.3 |
| Maximum CK during admission (iU/L) | 513 (200, 1370) |
| Cardiovascular risk factors | |
| Current smoking | 40.5 |
| Diabetes mellitus | 23.5 |
| Hypertension | 55.5 |
| Hypercholesterolaemia | 49.3 |
| Cardiovascular history | |
| Prior percutaneous coronary intervention | 26.2 |
| Prior coronary artery bypass grafting | 10.0 |
| Prior myocardial infarction | 26.9 |
| Prior heart failure | 2.4 |
| Valvular heart disease | 2.2 |
| Prior stroke | 9.0 |
| Peripheral artery disease | 8.9 |
| Medication at first blood sample moment | |
| Aspirin | 95.3 |
| P2Y12 inhibitor | 95.2 |
| Vitamin K antagonist | 6.8 |
| Statin | 96.2 |
| β-blocker | 89.8 |
| ACE inhibitor or ARB | 82.9 |
Continuous data are presented as median (25th, 75th percentiles) values. Categorical data are presented as percentages. There are no missing data for any of the aforementioned variables.
ARB, angiotensin II receptor blocker; CK, creatine kinase; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main coronary artery; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; RCA, right coronary artery; STEMI, ST-elevation myocardial infarction; UAP, unstable angina pectoris.